Spots Global Cancer Trial Database for Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone
Official Title: A Phase II Study of Everolimus and Sorafenib in Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Sorafenib Alone
Study ID: NCT01263951
Conditions
Study Description
Brief Summary: The goal of this study is to determine the effect of combining everolimus and sorafenib in patients with metastatic differentiated thyroid cancer who progressed on sorafenib alone.
Detailed Description: The purpose of this research study is to: 1. Find out if sorafenib and everolimus prevent the growth of tumors that have grown when treated with sorafenib alone 2. Find out how long one might benefit from treatment with sorafenib and everolimus 3. Find out what side effects this drug may cause 4. Measure the amount of sorafenib and everolimus in the blood and see if "markers" can be found to help understand who might benefit from sorafenib and everolimus.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Contact Details
Name: Marcia Brose, MD, PhD
Affiliation: Hospital of the University of Pennsylvania- Abramson Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
